Rehmann Capital Advisory Group lowered its position in shares of Clorox Co. (NYSE:CLX) by 19.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,402 shares of the company’s stock after selling 563 shares during the period. Rehmann Capital Advisory Group’s holdings in Clorox were worth $332,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Destination Wealth Management increased its stake in shares of Clorox by 165.6% in the second quarter. Destination Wealth Management now owns 18,192 shares of the company’s stock worth $2,518,000 after buying an additional 11,342 shares during the last quarter. Albion Financial Group UT increased its stake in shares of Clorox by 1.1% in the second quarter. Albion Financial Group UT now owns 39,629 shares of the company’s stock worth $5,484,000 after buying an additional 436 shares during the last quarter. Bank of Montreal Can acquired a new stake in shares of Clorox during the second quarter worth approximately $53,902,000. Financial Architects Inc increased its stake in shares of Clorox by 46.4% in the second quarter. Financial Architects Inc now owns 3,625 shares of the company’s stock worth $502,000 after buying an additional 1,149 shares during the last quarter. Finally, Shell Asset Management Co. increased its stake in shares of Clorox by 9.6% in the second quarter. Shell Asset Management Co. now owns 103,486 shares of the company’s stock worth $14,321,000 after buying an additional 9,034 shares during the last quarter. 70.17% of the stock is owned by institutional investors.

Clorox Co. (NYSE:CLX) traded up 0.63% during trading on Tuesday, hitting $123.44. The stock had a trading volume of 1,120,012 shares. The company has a market cap of $15.98 billion, a price-to-earnings ratio of 25.09 and a beta of 0.33. The company has a 50-day moving average price of $129.50 and a 200-day moving average price of $130.10. Clorox Co. has a 52-week low of $113.37 and a 52-week high of $140.47.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.28 by $0.02. Clorox had a return on equity of 296.91% and a net margin of 11.25%. The company earned $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. During the same period in the prior year, the firm earned $1.44 earnings per share. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. Equities research analysts forecast that Clorox Co. will post $5.49 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 14th. Investors of record on Wednesday, October 26th will be given a $0.80 dividend. The ex-dividend date is Monday, October 24th. This represents a $3.20 annualized dividend and a yield of 2.59%. Clorox’s dividend payout ratio (DPR) is presently 64.91%.

A number of brokerages recently commented on CLX. Atlantic Securities raised Clorox from a “hold” rating to a “buy” rating and set a $144.00 price target for the company in a research report on Friday. B. Riley reaffirmed a “neutral” rating and set a $109.00 price target on shares of Clorox in a research report on Tuesday, August 9th. Citigroup Inc. increased their price target on Clorox from $134.00 to $144.00 and gave the company a “neutral” rating in a research report on Monday, August 8th. Zacks Investment Research raised Clorox from a “hold” rating to a “buy” rating and set a $148.00 price target for the company in a research report on Monday, August 8th. Finally, Goldman Sachs Group Inc. reaffirmed a “neutral” rating and set a $130.00 price target on shares of Clorox in a research report on Thursday, August 4th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the stock. Clorox currently has a consensus rating of “Hold” and a consensus price target of $128.90.

In related news, SVP Jon M. Balousek sold 5,136 shares of the company’s stock in a transaction that occurred on Monday, August 29th. The stock was sold at an average price of $131.14, for a total value of $673,535.04. Following the transaction, the senior vice president now directly owns 15,384 shares of the company’s stock, valued at approximately $2,017,457.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Nikolaos A. Vlahos sold 925 shares of the company’s stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $133.07, for a total value of $123,089.75. The disclosure for this sale can be found here. 2.09% of the stock is owned by corporate insiders.

About Clorox

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

5 Day Chart for NYSE:CLX

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co. (NYSE:CLX).

Receive News & Ratings for Clorox Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.